Confluence Pharmaceuticals,LLC. logo

Confluence Pharmaceuticals,LLC.

Confluence's mission is doing research in Autism and Fragile X Syndrome and bring a solution that treats core social and communication impairments. Confluence is a biopharmaceutical company ficused on developing therapeutic treatments for core impairements associated with fragile X syndrome & autism spectrum disorders.

Confluence was founded by Dr. Craig A. Erickson, who while at Indiana university conducted the foundation work and than the initial IP was exclusively licensed to Confluence Pharmaceuticals by Indiana University.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.confluencepharma.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
4904 Deer Ridge Drive South Carmel, IN 46033
Indianapolis
United States
Email
Contact Number
+1 317 379 7498

In 2015, Confluence Pharmaceuticals signs Co-development and Marketing Agreement with AOP Orphan Pharmaceuticals for Fragile X Drug.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/confluence-pharmaceuticals-llc” connections=”true” suffix=””]

In Feb 2013, The John Merck Fund Awards Dr. Erickson (founder of Confluence) $1 Mn Research Grant, for treatment related research in fragile X syndrome.